Denosumab

Denosumab
Klinički podaci
Prodajno ime	Prolia, Ranmark, Xgeva
Drugs.com	Monografija
Način primene	Subkutano
Farmakokinetički podaci
Poluvreme eliminacije	25,4 dana

Identifikatori
CAS broj	615258-40-7^Y
ATC kod	M05BX04 (WHO)
DrugBank	DB06643^Y
ChEMBL	CHEMBL1237023^Y
Hemijski podaci
Formula	C₆₄₀₄H₉₉₁₂N₁₇₂₄O₂₀₀₄S₅₀
Molarna masa	144.7

Denosumab^[1] je ljudsko monoklonalno antitelo za tretman ostioporoze, gubitka koštane mase, koštanih metastaza, multiplog mijeloma, i tumora gigantskih ćelija kostiju.^[2]^[3] Ovaj lek je razvilo biotehnološko preduzeće Amgen.^[4] Denosumab je IgG2 monoklonalno antitelo koje je inhibira RANKL ligand.^[5]^[6]^[7]

Reference

^ Pageau, Steven C. (2009). „Denosumab”. MAbs. 1 (3): 210—215. PMC 2726593 . PMID 20065634. doi:10.4161/mabs.1.3.8592.
^ McClung, Michael R.; Lewiecki, E. Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson, Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D.; Lederman, Samuel N. (2006). „Denosumab in Postmenopausal Women with Low Bone Mineral Density”. New England Journal of Medicine. 354 (8): 821—31. PMID 16495394. doi:10.1056/NEJMoa044459.
^ Ellis, G. K.; Bone, H. G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. (2008). „Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer”. Journal of Clinical Oncology. 26 (30): 4875—82. PMID 18725648. doi:10.1200/JCO.2008.16.3832.
^ „Prolia (denosumab)”. Products. Amgen. Архивирано из оригинала 29. 09. 2015. г. Приступљено 6. 5. 2012.
^ Malan J, Ettinger K, Naumann E, Beirne OR: The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6. doi: 10.1016/j.oooo.2012.08.439. PMID 23159111
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди

Literatura

Walker, Emily P. (7. 2. 2012). „Benefit of Bone Drug in Prostate Cancer in Doubt”. MedPage Today.
Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Denosumab

Lekovi za tretman bolesti kostiju (M05)

Bisfosfonati

Azotni (Alendronska kiselina, ibandronska kiselina, inkadronska kiselina, pamidronska kiselina, risedronska kiselina, zoledronska kiselina)
bez-azotni (Etidronska kiselina, klodronska kiselina, tiludronska kiselina)

Koštani morfogenetički proteini

Dibotermin alfa • Eptotermin alfa

Drugi

Inhibitor resorpcije (Ipriflavon) • Aluminijum hlorohidrat • Koštani agens dualnog dejstva (Stroncijum ranelat) • RANKL inhibitor (Denosumab) • Katepsin K inhibitor (Odanakatib)

M: BON/CAR

anat(t,c,f,k,f,u,p,l)/phys/devp

noco/cong/tumr, sysi/epon, injr

proc, lek(M5)